0.0134USD+34.00%Mkt Cap: 401134 USDP/E: 0.00Last update: 2026-05-26
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. Its lead product candidate is istaroxime, which is in Phase 2b clinical…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap401.13K USD
Enterprise Value3.82M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-1.79M USD
Revenue/Share—
Last Price0.0134 USD
Fiscal Year EndDec 2024
MR QuarterSep 2025
Employees14
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)0.00
P/E (Forward)-0.01
PEG—
EV/EBITDA-0.25
EV/Revenue—
P/S—
P/B-0.06
EPS (TTM)323.08
EPS (Forward)-2.13
52W Range
0.01000% of range1.860
52W High1.860 USD
52W Low0.0100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-17.88%
ROA-6.41%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-15.40M USD
CapEx (TTM)12.00K USD
FCF Margin—
FCF Yield-5894.07%
Net Debt3.28M USD
Net Debt/EBITDA-0.21
Balance Sheet
Debt/Equity0.18
Current Ratio0.33
Quick Ratio0.01
Book Value/Sh-0.3450 USD
Cash/Share0.0060 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateApr 29, 2020
Splits
Last Split1:50
Split DateFeb 21, 2025
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.33.71M
Float33.71M
Insiders0.00%
Institutions0.02%
Short Interest
Short Ratio0.1d
Short % Float6.25%
Short % Out.6.25%
Shares Short1.79M
Short (prev mo.)561.82K
Technical
SMA 500.0164 (-18.3%)
SMA 2000.0711 (-81.2%)
Beta1.76
S&P 52W Chg28.31%
Avg Vol (30d)232.07K
Avg Vol (10d)130.22K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—